Cosentyx 9 year psoriasis patient study

[Fred]

This study included a cohort of patients with psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), all treated with subcutaneous Cosentyx (secukinumab) at the dose approved for each indication and observed throughout a 9-year period between 2015 and 2023.

Quote:

---

Secukinumab is a biologic agent known for its durable efficacy in chronic plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Monitoring the safety of secukinumab is a priority to ensure its long-term usage.

We aimed to provide an extended safety assessment of secukinumab treatment in a real-world setting. This bicentric observational study enrolled 332 patients with PsO, PsA and AS who received subcutaneous injections of secukinumab for up to 9 years.

Adverse events (AEs) were reported annually as exposure-adjusted incidence rates (EAIRs) per 100 patient-years (pt-y). The total secukinumab exposure was 1129 pt-y. The retention rate was 73%, with 16 (4.8%) of patients discontinuing due to AEs.

Despite most AEs being reported within the first 2 years, their incidence was low and decreased over time. The EAIR of any AEs was the highest in the initial 6 months (32.72/100 pt-y), followed by year 1 (7.62/100 pt-y), and year 2 of treatment (3.01/100 pt-y). Common AEs included respiratory and urinary tract infections, candidiasis, and diarrhoea.

Secukinumab showed sustained safety over an extended 9-year treatment period, supporting its use for the long-term management of these immune-inflammatory disorders.

Source: onlinelibrary.wiley.com

*Funding: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Cosentyx (secukinumab)